Thrombopoietin R產(chǎn)品信息
英文名稱:Thrombopoietin receptor
中文名稱:血小板生成素受體
靶點別稱:MPL,C-MPL,CD110,MPLV,THCYT2,TPOR
物種:Human
標(biāo)簽:His Tag
屬性:Protein
標(biāo)記:Unconjugated
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human Thrombopoietin R, His Tag (THR-H52H7) is expressed from human 293 cells (HEK293). It contains AA Gln 26 - Trp 491 (Accession # P40238-1 ).
Predicted N-terminus: Gln 26
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus
The protein has a calculated MW of 54.4 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
Thrombopoietin R分子背景
Thrombopoietin R, also known as TPO-R, is expressed predominantly on the surface of MKs, platelets, hemangioblasts, and hematopoietic stem cells (HSCs). Binding of TPO to the megakaryocyte TPO-R leads to different effects: prevention of megakaryocyte apoptosis; increased megakaryocyte number, size, and ploidy; increasing rate of megakaryocyte maturation; and internalization of the TPO/TPO-R complex. Thrombopoietin R involved in multiple signal transduction pathways, such as JAK, STAT, and MAP kinase.
關(guān)鍵字: Thrombopoietin R;Thrombopoietin R蛋白;血小板生成素受體;Thrombopoietin;Thrombopoietin受體;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。